
Benzinga Pro data, 4D Molecular Therapeutics (NASDAQ:FDMT) reported Q4 sales of $92.00 thousand. Earnings fell to a loss of $25.08 million, resulting in a 12.79% decrease from last quarter. 4D Molecular Therapeutics collected $1.37 million in revenue during Q3, but reported earnings showed a $22.24 million loss.